|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-4-6
|
|
pubmed:abstractText |
Quality of life (QOL) is significantly impaired in patients with acute myeloid leukemia (AML), and fatigue is the most common and disabling symptom; effective treatment measures have yet to be found. Cytokines, biomarkers of inflammation, may moderate both health outcomes, but published data are limited. We looked at the role of cytokines in modulating QOL and fatigue in an older AML population.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1433-7339
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
539-46
|
|
pubmed:meshHeading |
pubmed-meshheading:18931862-Aged,
pubmed-meshheading:18931862-Aged, 80 and over,
pubmed-meshheading:18931862-Biological Markers,
pubmed-meshheading:18931862-Cytokines,
pubmed-meshheading:18931862-Fatigue,
pubmed-meshheading:18931862-Female,
pubmed-meshheading:18931862-Humans,
pubmed-meshheading:18931862-Leukemia, Myeloid, Acute,
pubmed-meshheading:18931862-Male,
pubmed-meshheading:18931862-Middle Aged,
pubmed-meshheading:18931862-Pilot Projects,
pubmed-meshheading:18931862-Quality of Life,
pubmed-meshheading:18931862-Questionnaires,
pubmed-meshheading:18931862-Statistics, Nonparametric
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia.
|
|
pubmed:affiliation |
Department of Medicine, University Health Network, Toronto General Hospital, 200 Elizabeth Street (EN14-214), Toronto, Ontario M5G 2C4, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
